Suppr超能文献

丙吡胺:对持续性室性心动过速或心室颤动患者电生理效应及临床疗效的评估

Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation.

作者信息

Lerman B B, Waxman H L, Buxton A E, Josephson M E

出版信息

Am J Cardiol. 1983 Mar 1;51(5):759-64. doi: 10.1016/s0002-9149(83)80129-5.

Abstract

The efficacy of disopyramide in the management of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) was evaluated in 50 patients by programmed ventricular stimulation: 38 patients had coronary artery disease (16 with left ventricular aneurysm), 8 had other cardiac diseases, and 4 had no apparent heart disease. Disopyramide was administered orally for 72 hours (dosage 400 to 1,600 mg/day), resulting in a plasma level of 3.6 +/- 1.2 micrograms/ml (mean +/- standard deviation [SD]). Disopyramide prevented induction of sustained ventricular tachyarrhythmias in 17 patients (34%) and failed to prevent induction in 33 patients (66%). Plasma levels were not significantly different regardless of response to disopyramide. The VT cycle length in patients responding to disopyramide was shorter than in nonresponding patients (225 +/- 51 ms versus 281 +/- 70 ms, p = 0.005). Disopyramide increased VT cycle length in those patients in whom it was ineffective (failed to prevent induction) from 281 +/- 70 ms to 347 +/- 64 ms (p less than 0.001). Ventricular refractory periods, QRS, and QTc durations significantly increased after disopyramide administration. Of the 17 patients in whom tachyarrhythmias were noninducible on disopyramide, 11 were discharged on disopyramide and followed up for 19 +/- 9 months; 9 of them remained free of VT. Heart failure developed in 2 of these patients. One other patient in whom disopyramide was ineffective had irreversible heart failure and died. It is concluded that disopyramide (1) prevents induction of ventricular tachyarrhythmias in one third of patients studied and remains clinically effective in approximately 80%, (2) is more frequently effective in rapid tachycardias, (3) prolongs the VT cycle length when ineffective, and (4) may produce marked hemodynamic embarrassment in patients with significant left ventricular dysfunction.

摘要

通过程控心室刺激对50例患者评估了丙吡胺治疗持续性室性心动过速(VT)或室颤(VF)的疗效:38例患者患有冠状动脉疾病(16例有左心室室壁瘤),8例有其他心脏疾病,4例无明显心脏病。口服丙吡胺72小时(剂量400至1600毫克/天),血浆水平为3.6±1.2微克/毫升(均值±标准差[SD])。丙吡胺使17例患者(34%)未诱发出持续性室性快速心律失常,33例患者(66%)未能防止诱发。无论对丙吡胺的反应如何,血浆水平无显著差异。对丙吡胺有反应的患者的VT周期长度短于无反应的患者(225±51毫秒对281±70毫秒,p = 0.005)。丙吡胺对无效(未能防止诱发)的患者,使VT周期长度从281±70毫秒增加到347±64毫秒(p<0.001)。服用丙吡胺后心室不应期、QRS及QTc间期显著延长。在17例服用丙吡胺后未诱发出快速心律失常的患者中,11例出院时服用丙吡胺并随访19±9个月;其中9例未再发生VT。这些患者中有2例发生心力衰竭。另1例对丙吡胺无效的患者有不可逆性心力衰竭并死亡。结论是丙吡胺:(1)在三分之一的研究患者中可防止诱发室性快速心律失常,且约80%在临床上仍有效;(2)对快速性心动过速更常有效;(3)无效时可延长VT周期长度;(4)对有明显左心室功能障碍的患者可能产生明显的血液动力学障碍。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验